Novamab specializes in the research and development of nanobodies, a type of small antibody fragment that offers targeted therapeutic applications for respiratory diseases, autoimmune disorders, and cancer. The company provides a fully integrated platform for the development, formulation, and production of these nanobody-based drugs, enhancing treatment efficacy and patient convenience.
Funding
$24.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current treatments for respiratory diseases, autoimmune disorders, and cancer often lack precise targeting, leading to systemic side effects and reduced efficacy. Traditional antibody therapies can be expensive to produce and may have limitations in penetrating dense tissues or reaching specific intracellular targets.
Solution
Novamab develops nanobody-based therapeutics, leveraging the unique properties of these small antibody fragments to create targeted treatments for a range of diseases. Their integrated platform covers the entire nanobody drug development process, from discovery and formulation to manufacturing. Nanobodies' small size and high stability enable enhanced tissue penetration, improved target binding, and potential for oral or inhaled delivery, offering improved efficacy and patient convenience compared to conventional antibodies. The company's pipeline includes nanobodies targeting respiratory illnesses, autoimmune conditions, and various cancers.
Target Audience
Novamab's primary customers are pharmaceutical companies seeking novel therapeutic candidates for licensing or co-development, as well as clinical researchers investigating new treatment modalities for respiratory diseases, autoimmune disorders, and cancer.
Features
- Fully integrated nanobody development platform encompassing discovery, engineering, and production
- Nanobodies with high affinity and specificity for disease-relevant targets
- Streamlined manufacturing process for cost-effective production
- Potential for multi-specific nanobodies to target multiple pathways simultaneously
- Nanobodies engineered for improved stability, solubility, and reduced immunogenicity
- Versatile delivery options, including intravenous, subcutaneous, inhaled, and oral formulations